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Functional Dissociation of m Opioid Receptor
Signaling and Endocytosis: Implications
for the Biology of Opiate Tolerance and Addiction
If this is the case, how could opiate drugs differ in
their effects on the m opioid receptor? It is well estab-
lished that individual opiate drugs differ quantitatively
in the affinity with which they bind receptors or the
strength with which they activate receptors after bind-
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ing activation. Specifically, individual opiate ligands dif-
fer greatly in their ability to induce rapid endocytosis of
opioid receptors both in cultured cells and native neu-Summary
rons (Keith et al., 1996, 1998; Sternini et al., 1996). As this
process is associated with functional desensitizationOpiate analgesia, tolerance, and addiction are medi-
of receptor-mediated signal transduction (Whistler andated by drug-induced activation of the m opioid recep-
von Zastrow, 1998; Zhang et al., 1998), differential ef-tor. A fundamental question in addiction biology is
fects of opiate drugs on this regulatory mechanism maywhy exogenous opiate drugs have a high liability for
be of great physiological importance.inducing tolerance and addiction while native ligands
As intriguing as this possibility may be, it is also con-do not. Studies indicate that highly addictive opiate
ceivable that differences in the abilities of individualdrugs such as morphine are deficient in their ability
opiate drugs to facilitate regulation of receptor-acti-to induce the desensitization and endocytosis of re-
vated signaling by endocytosis may merely reflect pre-ceptors. Here, we demonstrate that this regulatory
viously recognized quantitative differences in the rela-mechanism reveals an independent functional prop-
tive strength with which these individual drugs initiallyerty of opiate drugs that can be distinguished from
activate receptors and thus provide no additional insightpreviously established agonist properties. Moreover,
into opiate drug action. Indeed, a close correlation be-this property correlates with agonist propensity to pro-
tween activation and endocytic regulatory actions ofmote physiological tolerance, suggesting a fundamen-
ligands for other heptahelical receptors has been re-tal revision of our understanding of the role of receptor
ported (Szekeres et al., 1998), and a similar relationshipendocytosis in the biology of opiate drug action and
has been suggested to exist for opiate drugs (Kovoor etaddiction.
al., 1998). Thus, the question of whether the differential
effects of clinically important opiate drugs on the endo-Introduction
cytic regulation of opioid receptors represents an inde-
pendent functional property of opiate agonists is of criti-
Alkaloid analgesic drugs such as morphine activate the
cal importance to understanding the action of addictive
same heptahelical receptors as native opioid peptide
opiate drugs. This question is especially significant in
ligands. However, many opiate drugs are highly ad- light of the well-established role of endocytosis in the
dictive, while endogenously released peptide ligands desensitization and downregulation of receptor-medi-
are not. An important distinction between opiate drugs ated signaling, both of which have been implicated in
and native peptides is that these two classes of ligand the development of tolerance and dependence to opiate
differ greatly in bioavailability and metabolism. Never- drugs. In addition, because heptahelical receptors com-
theless, there are also significant differences in the abil- prise the largest class of neurotransmitter receptors and
ity of individual opiate drugs to induce physiological are the molecular targets of most neuropsychiatric
tolerance when administered at equieffective analgesic drugs, this question is also of fundamental relevance to
doses (Rezvani et al., 1983; Duttaroy and Yoburn, 1995; molecular neurobiology.
Mercadante et al., 1998). These results suggest that We have addressed this important question by di-
there may be significant variability in the actions of dis- rectly comparing agonist activity of individual opiate
tinct alkaloid drugs on individual subtype(s) of opioid ligands with their ability to induce regulatory endocyto-
receptor, which could underlie differences in their liabil- sis of m opioid receptors in the same cell background.
ity for inducing the tolerance and dependence observed Using this approach, we demonstrate that the abilities
clinically and in animal studies. Importantly, targeted of certain clinically important opiate drugs to activate
disruption of the m opioid receptor gene abrogates anal- receptor-mediated signaling and endocytosis are not
gesia, tolerance, and dependence induced by a variety directly correlated and are, in fact, inversely correlated
of opiate drugs (Matthes et al., 1996), thus raising the in some cases. Furthermore, we identify a cytoplasmic
possibility that differences in the addictive properties domain of the m opioid receptor that specifically controls
of individual opiate ligands reflect differences in the the ability of opiate agonists to induce receptor endocy-
functional effects of these drugs on the m opioid receptor tosis, thereby confirming mutationally the dissociation
itself. between these functional properties of individual ligands.
Moreover, we demonstrate that altering the ability of
certain opiate drugs to induce regulatory endocytosis‖To whom correspondence should be addressed (e-mail: zastrow@
itsa.ucsf.edu). of receptors causes profound effects on drug-induced
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Figure 1. m Opioid Receptors Demonstrated
Agonist-Selective Endocytosis
(a) FLAG-tagged m opioid receptors (mORs)
remained predominantly in the plasma mem-
brane in cells incubated in the absence of
agonist (NT). mORs in cells incubated with
5 mM of the agonists DAMGO, methadone
(MD), or etorphine (ET) were endocytosed,
as indicated by redistribution of antibody-
labeled receptors from the plasma membrane
to numerous endocytic vesicles. Morphine (MS)
or the mixed agonist/antagonist buprenor-
phine (Bup) failed to induce detectable endo-
cytosis of the mOR.
(b) Internalization of receptors in response to
each agonist examined in (a) was confirmed
biochemically using cell surface biotinylation
and protection, where internalized receptors
are protected from cleavage by membrane-
impermeant reducing agent.
(c) The relative activity of the agonists
DAMGO, morphine (MS), and methadone
(MD) for causing rapid internalization of the
mOR was quantitated by immunofluores-
cence flow cytometry.
desensitization of receptor-mediated signal transduc- stably transfected HEK 293 cells (z105 receptors/cell).
Receptors expressed in this manner are functional andtion. Finally, we demonstrate that mechanisms distin-
guishing the endocytic regulatory effects of opiate drugs exhibit membrane trafficking properties closely similar
to those of native receptors expressed endogenouslyare conserved when mutant receptors are expressed in
primary-cultured neurons, suggesting that these obser- in native neurons (Keith et al., 1996, 1998; Sternini et
al., 1996), and rapid endocytosis of receptors observedvations are likely to be relevant to the physiological
action of opiate drugs on native neurons. in these cells is a reliable indicator of arrestin-dependent
regulation of downstream signaling (Whistler and vonThus, we have defined a novel functional property that
distinguishes individual opiate drugs and is distinct from Zastrow, 1998; Zhang et al., 1998).
While the opioid peptide DAMGO promoted the rapidpreviously defined parameters that characterize these
drugs. These results constitute direct evidence that endocytosis of m opioid receptors, morphine failed to
promote detectable endocytosis of receptors followingdrugs can selectively manipulate distinct functional
properties of any heptahelical receptor, and they sug- prolonged activation, even when present at extremely
high concentrations (Figure 1a). The failure of morphinegest a significant revision to the well-accepted molecu-
lar mimicry hypothesis of opiate drug action. Further- to stimulate the rapid endocytosis of m opioid receptors
was not a general property of alkaloid agonists, as twomore, as the relative activity of certain opiate drugs to
induce regulatory endocytosis of receptors appears to other clinically relevant drugs structurally related to mor-
be inversely correlated with previous estimates of the phine, etorphine and methadone, stimulated rapid endo-
relative ability of these drugs to induce physiological cytosis of m opioid receptors as efficiently as peptide
tolerance in vivo (Rezvani et al., 1983; Duttaroy and agonist (Figure 1a). These observations were confirmed
Yoburn, 1995; Mercadante et al., 1998), our findings at saturating agonist concentration (to obviate any possi-
suggest a fundamentally different hypothesis for the role ble effects of agonist potency) using two independent
of opioid receptor regulation in the biology of drug ad- quantitative assays for net receptor internalization (cell
diction. surface biotinylation and protection, Figure 1b, and fluo-
rescence flow cytometry, Figure 1c). These experiments
established the relative rank order of selected agonistsResults
We examined ligand-induced signaling and endocytosis for inducing endocytosis of opioid receptors as DAMGO ≈
methadone ... morphine.of an epitope-tagged m opioid receptor expressed in
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Opioid receptors signal by catalyzing ligand-depen-
dent nucleotide exchange on Gi and Go, thereby inhib-
iting adenylyl cyclase, inhibiting N-type calcium chan-
nels, and activating G protein±gated inwardly rectifying
potassium (GIRK) -type potassium channels. Previously,
we and others have demonstrated that morphine and
DAMGO inhibit adenylyl cyclase to a similar extent in
cells expressing m opioid receptors at levels similar to
or greater than those observed in native neurons
(Traynor and Nahorski, 1995; Keith et al., 1996). How-
ever, opioid receptor±mediated inhibition of adenylyl cy-
clase activity in these cells typically does not require
full receptor occupancy (Chavkin and Goldstein, 1984;
Costa et al., 1992), and maximal inhibition of adenylyl
cyclase observed in various cell types is independent
of receptor density (Chakrabarti et al., 1995). Thus, this
signaling readout is relatively insensitive to differences
in agonist efficacy. In contrast, opioid receptor±induced
activation of inwardly rectifying potassium channels re-
quires significantly higher levels of agonist occupancy
and is dependent on receptor density (Kovoor et al.,
1998), thereby allowing quantitative differences in the
agonist activity of individual ligands to be delineated in
cells expressing physiologically relevant levels of recep-
tor protein.
We introduced GIRK1/4 channels by stable transfec-
tion into the same m opioid receptor±expressing cells
in which the endocytosis assays were performed. To
determine relative activities of individual agonists for
inducing G protein±mediated signal transduction, we Figure 2. Relative Order of Activity of m Opioid Receptor Ligands
for Inducing G Protein±Mediated GIRK Activationmeasured receptor-dependent activation of GIRK cur-
(a) The ability of saturating concentrations (1 mM) of morphine,rents in whole cells. While the agonists tested were
DAMGO, and methadone to activate GIRK1/4 was measured in cellschosen because they exhibit similar potencies and affin-
stably transfected with mORs and GIRK1/4 channels. To determineities at the m opioid receptor, all agonists were applied
relative signaling activities, pair-wise agonist application was
at a saturating concentration (1 mM) to obviate any pos- adopted. Receptors were activated first with 1 mM morphine, fol-
sible effects of agonist potency on receptor-mediated lowed by washout and application of the second agonist also at
signaling. To assure reliable within-cell comparison in 1 mM. Relative activity for each agonist was expressed as the ratio
of the two steady-state currents (second agonist/first morphine).all cases, whole-cell currents were recorded while mor-
The continuous trace shown on top was from two pulses of 1 mMphine was applied first and then washed away, and the
morphine application. The current±voltage relationship of the in-second agonist (morphine, DAMGO, or methadone) was
duced GIRK current was revealed by the ramp pulse. Membrane
applied immediately thereafter (Figure 2a). While mor- was held at 0 mV, followed by two 5 ms steps to 110 and 120 mV,
phine was observed to be a marginally less active ago- and then jumped to 60 mV for 10 ms to assure correct activation
nist than DAMGO in some cells, there was no significant kinetics of GIRK currents. Immediately after the three test pulses,
membrane potential was ramped from 100 to 120 mV in a 200 msdifference detected between the relative agonist activi-
interval.ties of morphine and DAMGO using this assay when
(b) Slope conductances were measured in multiple cells betweenelectrophysiological responses were averaged over
90 and 70 mV to reflect the level of GIRK activation induced by
multiple cells. In contrast, methadone was a substan- ligand. By this measurement, morphine's ability to activate receptor
tially less-active agonist of GIRK activation in all cells was similar to that of DAMGO and significantly greater than that of
examined, and a significant reduction in relative agonist methadone.
activity (compared to both DAMGO and morphine) was
confirmed by analysis of multiple cells (Figure 2b). Thus, differences in the ability of these drugs to induce recep-
the rank order of agonist activity for receptor-mediated tor-mediated signaling via heterotrimeric G proteins.
signal transduction in these cells stably expressing m We next examined whether the differential effects of
opioid receptors and a GIRK1/4 channel was DAMGO $ individual opiate drugs on receptor signaling and endo-
morphine .. methadone (Figure 2b), consistent with cytosis could also be dissociated mutationally. In partic-
the relative order of agonist activity measured in other ular, we examined whether modification of cytoplasmic
systems (Yu et al., 1997) but in marked contrast to the structures could influence the agonist selectivity of en-
rank order of these agonists to promote endocytosis docytosis. We replaced the cytoplasmic tail of the m
of receptors (see Figure 1). These results indicate that opioid receptor with the cytoplasmic tail of the d opioid
morphine truly is different from other opiate ligands. receptor. This chimeric receptor is a functional opioid
Specifically, differential effects of the individual opiate receptor that exhibits agonist affinity similar to that of
drugs morphine and methadone on internalization of the wild-type m opioid receptor (Afify et al., 1998). Re-
markably, although neither the wild-type m nor the dopioid receptors can be dissociated from quantitative
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Figure 3. m/d-Tail Chimeric Receptors Dem-
onstrated Altered Agonist Selectivity for En-
docytosis
(a) FLAG-tagged m/d-tail chimeric receptors
(m/d-tail-ORs) remained predominantly in the
plasma membrane in cells incubated in the
absence of agonist (NT). As for the mOR (Fig-
ure 1), m/d-tail-ORs internalized rapidly in the
presence of 5 mM of the agonists DAMGO,
methadone (MD), or etorphine (ET) but not
buprenorphine (Bup). In contrast to the wild-
type mOR, m/d-tail-ORs internalized rapidly in
response to morphine (MS).
(b) Internalization of m/d-tail-ORs in response
to each agonist examined in (a) was con-
firmed biochemically using cell surface bio-
tinylation and protection.
(c) The relative activity of DAMGO, morphine
(MS), and methadone (MD) for inducing rapid
internalization of m/d-tail-ORs was quanti-
tated by immunofluorescence flow cytometry.
opioid receptor endocytoses following activation by to express much lower levels of receptor protein, the
relative difference between morphine and DAMGO wasmorphine, morphine-induced endocytosis of the chi-
meric receptor was readily observed (Figures 3a±3c). more pronounced (compare Figures 4a and 4b).
Essentially identical results were obtained when theThis enhanced endocytosis is unlikely to reflect an en-
hanced ability of the chimeric receptor to couple to relative agonist activities of morphine and DAMGO were
compared in cells transiently transfected with the chi-heterotrimeric G proteins, because the ability of agonists
to induce G protein±mediated inhibition of adenylyl cy- meric receptor (Figures 4c and 4d). The relative order
of activity for DAMGO and morphine for both the mclase via this receptor is not enhanced (and is, in fact,
slightly reduced) relative to the wild-type m opioid recep- and the chimeric receptor was confirmed by measuring
ligand-induced GIRK currents in multiple cells selectedtor (Afify et al., 1998). Thus, mutation of a single cyto-
plasmic domain appears to specifically influence the at random from each cell population. This analysis indi-
cated that the tail substitution caused no detectableagonist selectivity of opioid receptor endocytosis.
We next investigated whether altering the cytoplasmic effect on the relative agonist activity of morphine at the
chimeric receptor (Figure 4e). Importantly, we observedtail of the m opioid receptor altered the relative order of
activity of morphine and DAMGO for inducing G protein± that the relative activity of morphine and DAMGO for
both m and chimeric receptors was independent of themediated signal transduction. HEK 293 cells expressing
a GIRK1/2 channel (Chuang et al., 1998) were transiently order in which the agonists were applied. These obser-
vations confirm that the mutation of the receptor tailtransfected with either the m or the chimeric opioid re-
ceptor. This experimental design allowed agonist activ- specifically affected the relative activity of morphine for
inducing receptor endocytosis without changing the rel-ity to be examined in cells that express receptors over
a range of expression levels. Consistent with our results ative agonist activity for G protein±mediated signaling,
suggesting that the carboxy-terminal cytoplasmic do-in Figure 2, which measured GIRK1/4 activation in stably
transfected cells uniformly expressing the m opioid re- main of the receptor protein is able to distinguish the
regulatory properties of distinct activated conforma-ceptor, the agonist activity of morphine was closely simi-
lar to that of DAMGO in many of the transiently trans- tions of the receptor protein induced by structurally dis-
tinct agonists.fected cells (Figure 4a). However, in some cells, those
we assume from previous studies (Kovoor et al., 1998) The chimeric opioid receptor provided an opportunity
Dissociation of Opioid Signaling and Endocytosis
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Figure 4. The Relative Order of Activity of
Morphine and DAMGO Was Not Altered by
Replacing the Cytoplasmic Tail of the Re-
ceptor
HEK 293 cells expressing a GIRK1/2 channel
(Chuang et al., 1998) were transiently trans-
fected with either the m opioid receptor (a and
b) or the chimeric receptor (c and d). Agonist
was applied and recordings made as for Fig-
ure 2. Receptor-mediated activation of GIRK
currents by morphine and DAMGO were simi-
lar in many cells examined in the populations
of m (a) and chimera (c) -expressing cells,
consistent with the results obtained in Figure
2. In some cells present in the transiently
transfected populations expressing either
mORs or m/d-tail-ORs at relatively low levels
(see Discussion in text), differences between
the signaling activities of morphine and
DAMGO were more pronounced (b and d). In
(e), quantitation of these data over a large
number of cells, chosen at random from the
transiently transfected populations, revealed
no significant difference in the relative signal-
ing activity of morphine and DAMGO at the
m versus the chimeric receptor.
to examine the functional consequences of altering ago- the m receptor. Therefore, we examined the mechanism
by which the alteration of a single cytoplasmic domain,nist-specific endocytosis. To avoid complications that
may arise from desensitization due to the G protein cycle which is not expected to influence the structure of the
heptahelical receptor ªcoreº critical for ligand recogni-or effector regulation upon agonist treatment (Chuang
et al., 1998), we examined directly the coupling between tion and agonist-induced conformation change, pro-
moted morphine-induced endocytosis of the chimericm and chimeric opioid receptor proteins and G protein
by measuring nucleotide exchange activity in isolated receptor.
Both the m opioid receptor and the d opioid receptormembranes. m opioid receptors rapidly uncoupled from
heterotrimeric G proteins following activation by the endocytose via a dynamin-dependent mechanism in-
volving clathrin-coated pits (Keith et al., 1996; Whistlerpeptide agonist DAMGO but not following activation by
morphine (Figure 5a). In contrast, the chimeric receptor and von Zastrow, 1998). We observed that endocytosis
of the chimeric receptor, in response to both DAMGOexhibited nearly complete uncoupling from G protein
following activation by both DAMGO and morphine (Fig- and morphine, was also mediated by a dynamin-depen-
dent mechanism (data not shown). Previously, we andure 5b). These results confirm that the receptor mutation
changes the agonist selectivity of not only endocytosis others have demonstrated that overexpression of either
arrestin (Whistler and von Zastrow, 1998) or G protein±but also receptor±G protein uncoupling, both of which
influence downstream signaling (Whistler and von Zas- coupled receptor kinase (GRK) (Zhang et al., 1998) can
facilitate endocytosis of morphine-activated opioid re-trow, 1998).
It is somewhat remarkable that, while neither the m ceptors, suggesting that morphine-activated receptors
are in a conformation that is recalcitrant to the GRK-nor the d opioid receptor endocytoses following activa-
tion by morphine (Keith et al., 1996), a chimeric receptor mediated phosphorylation and arrestin binding involved
in promoting dynamin-dependent endocytosis. Indeed,derived from these receptors does so with high effi-
ciency. The wild-type d opioid receptor binds morphine extensive previous studies indicate that both d and m
opioid receptors are phosphorylated on multiple serine/poorly compared to the m receptor (Raynor et al., 1994).
In contrast, the chimeric mutant receptor has similar threonine sites located in the carboxy-terminal cyto-
plasmic tail (Pei et al., 1995; Trapaidze et al., 1996; Zhangpharmacology to the m receptor (Afify et al., 1998), con-
sistent with the transmembrane and extracellular do- et al., 1996). Therefore, we investigated the hypothesis
that the tail substitution generates a chimeric receptormains involved in ligand recognition being identical to
Neuron
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Figure 5. m/d-Tail Chimeric Receptors Exhib-
ited Functional Uncoupling from G Protein
following Morphine Activation
Cells stably expressing either mORs or m/d-
tail-ORs were pretreated for 5 min with
DAMGO (DG) or morphine (MS) or left un-
treated, and receptor±G protein coupling was
estimated by assaying the GTPgS binding in-
duced by agonist rechallenge of washed
membranes. Receptors from both cell lines
that were not pretreated with agonist stimu-
lated GTP exchange efficiently with both
DAMGO (DG) and morphine (MS) ([a] and [b],
shaded bars). mORs pretreated with DAMGO
(DG) were very inefficient at promoting GTP
exchange upon DAMGO restimulation ([a],
closed bar), indicating that the mORs in these
cells had become uncoupled from G protein
during the DAMGO pretreatment. mORs pretreated with morphine (MS) were still as effective as untreated receptors at promoting GTP exchange
upon DAMGO restimulation ([a], open bar) indicating that pretreatment with morphine failed to uncouple the receptors from G protein. m/d-
tail-ORs pretreated with DAMGO (DG) were also inefficient at promoting GTP exchange upon DAMGO restimulation ([b], closed bar), indicating
that the chimeric receptors in these cells had become uncoupled from G protein during the DAMGO pretreatment. In addition, m/d-tail-ORs
pretreated with morphine (MS) were also very ineffective at promoting GTP exchange upon DAMGO restimulation ([b], open bar), differing
markedly from morphine-pretreated mORs and demonstrating that morphine facilitated functional uncoupling of the chimeric receptor from
G protein.
that is a better substrate for regulatory phosphorylation the utility of GFP-tagged b-arrestin for monitoring ago-
and arrestin interaction than is the wild-type m opioid nist-specific regulation of opioid receptors (Barak et al.,
receptor when these receptors are in the morphine-acti- 1997; Zhang et al., 1998). Importantly, morphine-acti-
vated conformation. vated chimeric receptors strongly promoted recruitment
The wild-type m opioid receptor was phosphorylated of GFP±arrestin (Figure 6b), consistent with the pro-
in intact HEK 293 cells at a low level in the absence of nounced morphine-induced phosphorylation of the chi-
agonist, and receptor phosphorylation was enhanced mera (Figure 6a). Taken together, these observations
z2-fold when receptors were activated with etorphine strongly support the hypothesis that we have created a
(Figure 6a) or DAMGO (data not shown). Consistent with gain-of-function phenotype in the chimeric receptor by
our results and previous studies of m receptor phosphor- combining the pharmacology of the m opioid receptor
ylation in various cell types (Zhang et al., 1996, 1998), with the enhanced kinase substrate activity of the d tail.
morphine failed to cause any detectable phosphoryla- Thus, the chimeric receptor, in contrast to wild-type opioid
tion of the wild-type m opioid receptor above the consti- receptors, can undergo sufficient morphine-induced
tutive background level (Figure 6a). Wild-type d receptors phosphorylation to efficiently recruit b-arrestin and un-
expressed at similar levels are strongly phosphorylated dergo rapid, dynamin-dependent endocytosis.
following activation by opioid peptide or etorphine (Mur- To examine whether conformational mechanisms
ray et al., 1998) but not morphine (data not shown), mediating the agonist specificity of opioid receptor
consistent with previous studies demonstrating that the regulation in our transfected cell model system are phys-
cytoplasmic tail of the d opioid receptor is a highly favor- iologically relevant to native neurons, we utilized adeno-
able site for GRK-mediated phosphorylation (Pei et al., virus-mediated gene transfer to express epitope-tagged
1995) and that this receptor exhibits more pronounced versions of the wild-type or chimeric m opioid receptor
GRK-mediated desensitization than the m receptor in in primary cultures of rat hippocampal neurons. Both the
Xenopus oocytes (Kovoor et al., 1997). Phosphorylation wild-type and chimeric receptors were localized primar-
of the chimeric receptor, like the wild-type d receptor, ily in the plasma membrane of the cell body and neurites
was strongly stimulated by etorphine (Figure 6a) or
in the absence of agonist and, as expected, exhibited
DAMGO (data not shown). Remarkably, phosphorylation
rapid internalization in the presence of DAMGO or etor-
of the chimeric receptor was also strongly stimulated
phine (data not shown). However, the distribution ofby morphine (Figure 6a), in marked contrast to the ab-
the two receptors following morphine stimulation wassence of detectable morphine-induced phosphorylation
dramatically different. Wild-type m opioid receptors re-of the wild-type m or d opioid receptor.
mained in the plasma membrane following activationWe next examined whether alterations in ligand-
with morphine (Figure 7, left), consistent with the failuredependent phosphorylation were associated with differ-
of morphine to induce endocytosis of native m opioidences in membrane recruitment of b-arrestins. Consis-
receptors in neurons. In marked contrast, the chimerictent with its failure to induce detectable phosphorylation
receptor rapidly endocytosed in the presence of mor-or rapid endocytosis of the wild-type m opioid receptor,
phine when examined at similar expression levels undersaturating concentrations of morphine failed to cause
identical experimental conditions (Figure 7, right). Thus,detectable membrane recruitment of GFP-tagged ar-
mechanisms and receptor determinants mediating therestin 3 (b-arrestin 2) (Figure 6b; see also Zhang et al.,
ligand-selective endocytosis of opioid receptors are1998) in cells expressing wild-type m opioid receptor.
conserved, suggesting our observations are likely to beIn contrast, etorphine-activated m receptors efficiently
relevant to regulation of receptor-mediated signalingrecruited GFP-tagged arrestin to membrane puncta (Fig-
ure 6b), in agreement with previous studies establishing and thus the actions of opiate drugs in native neurons.
Dissociation of Opioid Signaling and Endocytosis
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Figure 6. The m/d-Tail Chimeric Receptor Was Phosphorylated and Recruited Arrestin following Activation by Morphine
(a) HEK 293 cells stably expressing either FLAG-tagged mORs or m/d-tail-ORs were metabolically labeled with 32P inorganic phosphate and
treated with morphine, etorphine, or left untreated, and receptor phosphorylation was examined by SDS±PAGE autoradiography of anti-
FLAG immunoprecipitates. Negligible nonspecific signal was observed in control immunoprecipitates from untransfected cells (293). In cells
expressing mOR, morphine (MS) failed to induce detectable receptor phosphorylation above the constitutive level observed in cells incubated
in the absence of agonist (NT). Incubation of cells with etorphine (ET) enhanced phosphorylation of the mOR z2-fold. Phosphorylation of the
m/d-tail-OR was much more strongly stimulated by etorphine (compare ET with NT in the right panel versus the left panel). In addition, morphine
(MS) strongly stimulated phosphorylation of the m/d-tail-OR, in contrast to its lack of detectable effect on the mOR.
(b) HEK 293 cells stably expressing either mOR or m/d-tail-OR were transiently transfected with GFP±arrestin 3 (Barak et al., 1997) and incubated
for 10 min in the presence of the indicated agonist, and localization of receptor and arrestin were examined by fluorescence microscopy.
mOR (left) exhibited pronounced internalization in response to etorphine but not morphine (top). The corresponding images of GFP±arrestin
(bottom) demonstrated that etorphine activation induced punctate membrane recruitment of arrestin, whereas activation of the mOR with
morphine failed to cause membrane recruitment of arrestin. In contrast, the m/d-tail-OR (right) internalized (top) and mediated pronounced
membrane recruitment of arrestin (bottom) following activation by both etorphine and morphine.
Discussion clinically important opiate analgesic drugs such as mor-
phine and methadone. This agonist property profoundly
effects the regulation of downstream signaling and canTaken together, our results suggest that differences in
the ability of select opioid agonists to mediate regulation be distinguished both pharmacologically and muta-
tionally from other important functional parameters suchof receptor signaling by rapid endocytosis represents
an independent functional property that distinguishes as potency and intrinsic activity for receptor activation.
Figure 7. The m/d-Tail Chimeric Receptor Ex-
hibited Morphine-Induced Endocytosis in
Neurons
Rat hippocampal neurons from 3-week-old
cultures were infected with adenovirus ex-
pressing epitope-tagged mOR or m/d-tail-OR
and allowed to recover for 2 days. Cells were
fed antibody to label cell surface receptors
and then treated with 5 mM morphine, fixed,
and processed for immunocytochemical lo-
calization of mOR (left) or m/d-tail-OR (right).
While the mORs remained predominantly on
the plasma membrane upon morphine stimu-
lation, m/d-tail-ORs were rapidly redistributed
to endocytic vesicles following activation by
morphine.
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Nevertheless, agonists with similar intrinsic activitiesTable 1. RAVE Values for Individual m Opioid Receptor Agonists
could have different RAVE values if they promoted differ-
DAMGO Morphine Methadone
ent levels of receptor endocytosis. For example, even
Activity (normalized current) 0.86 0.83 0.58 under receptor-limited conditions in Xenopus oocytes,
Relative activity (A) 1 0.97 0.67 which enhance observed differences in relative agonist
Endocytosis (% receptor 37 9 28 activity, the opiate agonists DAMGO and fentanyl have
internalized)
essentially identical intrinsic activities for GIRK activa-Relative endocytosis (E) 1 0.25 0.78
tion (Kovoor et al., 1998). However, fentanyl stimulates
RAVE (A/E) 1 3.88 0.86 less endocytosis in mammalian cells than does DAMGO
RAVE value was defined as relative activity versus endocytosis or (Keith et al., 1998). Thus, we would predict that fentanyl
A/E. Activity in this case was measured as normalized current and would have a RAVE value greater than that of DAMGO
endocytosis as percent receptor internalized measured by fluores- and more similar to that of morphine.
cence flow cytometry. The peptide DAMGO was defined as having What might be the physiological consequences of
activity and endocytosis of 1 and thus a RAVE of 1. Morphine has
these fundamental differences among individual drugsa RAVE significantly greater than 1, reflecting its relatively poor
in their ability to induce the rapid regulation of opioidability to stimulate endocytosis despite its ability to activate signal-
receptors by endocytosis? Clinical observations and an-ing. Methadone has a RAVE somewhat less than 1, reflecting its
relatively good ability to stimulate endocytosis despite its relatively imal studies indicate that significant differences do in-
poor ability to activate signaling. deed exist among individual opiate analgesic drugs with
respect to their tendency to promote physiological toler-
ance and dependence. For example, both methadone
and etorphine have been reported to induce less toler-Thus, the differences in endocytic regulation reflect fun-
ance than morphine (Rezvani et al., 1983; Duttaroy anddamental differences between individual opiate drugs
Yoburn, 1995; Mercadante et al., 1998) when adminis-in their ability to facilitate the dynamic regulation of
tered chronically at equieffective analgesic doses. Ouropioid receptor signaling. Importantly, while the exis-
estimates indicate that both of these drugs have RAVEtence of this distinct functional property has been es-
values similar to those of opioid peptide and much lesstablished most clearly using a model cell system, our
than morphine (Table 1 and data not shown). It will bestudies of primary cultured neurons suggest that the
important in future studies to examine the relationshipmechanisms underlying the agonist specificity for opioid
between RAVE values of additional opiate drugs mea-receptor endocytosis also operate in native neurons, con-
sured in cultured cells with their relative addictive liabili-sistent with the pronounced agonist specificity of recep-
ties observed in an animal model.tor internalization observed previously in studies of na-
We propose that the arrestin-mediated regulation oftive m opioid receptors in the intact brain (Keith et al., 1998).
opioid receptors by endocytosis (Whistler and von Zas-One way to define this independent property of an
trow, 1998; Zhang et al., 1998) may actually serve aindividual ligand is to express its ability to activate re-
protective role in reducing the development of physio-ceptors and drive their endocytosis as a ratio. Such a
logical drug tolerance. Specifically, we propose that a
ratio can be derived from the present data using the
suite of highly conserved receptor regulatory mecha-
relative ability of individual agonists to activate GIRK-
nisms, mediated by GRK and arrestin interaction with
type potassium channel conductance and promote
activated receptors (reviewed by Ferguson et al., 1998;
rapid endocytosis of receptors in the same cell back- Krupnick and Benovic, 1998; Lefkowitz et al., 1998),
ground. We refer to this independent property as RAVE serves to rapidly attenuate receptor-mediated signaling.
(for relative activity versus endocytosis). If we define the This regulation serves at least two roles. First, by func-
peptide agonist DAMGO as having a RAVE of 1 (Table 1), tional uncoupling of receptor and G protein, followed by
then morphine would have a RAVE substantially greater endocytosis, this arrestin-mediated regulation rapidly
than 1 (z4), as its relative ability to signal is much greater desensitizes cells to agonist. Second, following endocy-
than its relative ability to stimulate receptor endocytosis. tosis, receptors can be recycled to the cell surface in a
Conversely, methadone would have a RAVE somewhat fully active state, thereby resensitizing cells to agonist.
less than 1 (z0.8) and closer to that of opioid peptide (1), This dynamic cycle of receptor regulation may be de-
reflecting the ability of methadone to induce regulatory signed to mediate the dynamic actions of native opioid
endocytosis of receptors to a somewhat greater extent peptides, which are typically released in a phasic or
than its relative activity for promoting receptor-medi- pulsatile manner.
ated signal transduction. Opiate drugs, in contrast, persist in the extracellular
While use of this terminology emphasizes this func- milieu for a prolonged period of time because of their
tional difference between individual opiate agonists on resistance to proteolytic degradation and, hence, acti-
G protein±mediated signaling and desensitization by en- vate opioid receptors in an abnormally prolonged man-
docytosis, this difference is unlikely to represent the ner. Accordingly, opiate drugs that induce the rapid de-
only determinant of the differential effects of individual sensitization and endocytosis of receptors followed by
opiate drugs on receptor regulation. Indeed, opiate resensitization to agonist may more closely mimic the
drugs with similar RAVE values would be expected to phasic actions and physiological adaptations observed
differ in their effects on receptor regulation by endocyto- with native peptide ligands. In contrast, opiate drugs such
sis directly in proportion to their relative efficacies for as morphine persistently activate receptors, forcing other
receptor activation as suggested in a recent study com- cellular mechanisms to compensate at downstream site(s)
paring several opiate agonists on m opioid receptors for this prolonged activation. Thus, morphine could have
enhanced propensity to cause widespread changes inexpressed in Xenopus oocytes (Kovoor et al., 1998).
Dissociation of Opioid Signaling and Endocytosis
745
Guanine Nucleotide Exchange Assaysneural plasticity associated with drug addiction pre-
Membranes were prepared as previously described (Whistler andcisely because of its failure to effectively promote effi-
von Zastrow, 1998) after 5 min agonist treatment with either mor-cient arrestin-mediated regulation of the m opioid recep-
phine or DAMGO. Methods were used as described previously for
tor itself. GTPgS binding (Whistler and von Zastrow, 1998) using membranes
In contrast to the prevailing hypothesis, which pro- prepared as above unstimulated or stimulated with 5 mM DAMGO or
morphine for 30 min at 258C. Reactions were terminated by vacuumposes that desensitization of opioid receptors directly
filtration.contributes to physiological tolerance, our observations
suggest that the failure of morphine-activated receptors
Electrophysiologyto uncouple from G protein and endocytose appropri-
In Stable Cell Lineately may be critical for the high level of physiological
HEK 293 cells stably expressing GIRK1/4 channels and m opioid
tolerance induced by morphine. While the previous hy- receptor were trypsinized 24±48 hr before experiments and plated
pothesis was proposed based on the observation that onto coverslips. Experiments were performed in the tight-seal
whole-cell mode. The bath solution contained 10 mM HEPES (pHmorphine-tolerant animals exhibit a right-shifted dose±
7.4), 20 mM KCl, 120 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, and 5response curve for receptor-mediated signal transduc-
mM NaOH. The composition of the pipette solution was 9 mM HEPEStion measured in tissue preparations, consistent with a
(pH 7.2), 9 mM NaCl, 4.5 mM EGTA, 4.5 mM K2HPO4, 99 mM KCl,reduction in receptor reserve (Chavkin and Goldstein,
1.8 mM MgCl2, 0.5 mM CaCl2, 0.2 mM Na2GTP, and 18 mM NaOH.1984), such a reduction in agonist potency observed Series resistances of electrodes were within 3 MV and compensated
over a prolonged time period is also consistent with to at least 95%. To measure the m receptor±activated GIRK currents,
a ramp protocol, as depicted in the Figure 2 legend, was appliedother modifications of the signal transduction system.
repetitively every second. Whole-cell potassium currents were ex-Indeed, a number of studies indicate that morphine fails
pressed as the total potassium conductance in the membrane. Datato promote significant downregulation of m opioid recep-
were filtered at 2 kHz and sampled at 1 kHz.tors even under conditions that induce profound physio-
In Transiently Transfected Cells
logical tolerance (Lenoir et al., 1984; Simantov et al., HEK 293 cells expressing a GIRK1/2 channel (Chuang et al., 1998)
1984). Thus, we anticipate that downstream regulatory were transiently transfected with either the m or the chimeric opioid
receptor and recordings were taken as above.responses induced by the failure of morphine to promote
efficient arrestin-mediated desensitization may include
Receptor Phosphorylation and Immunoprecipitationadditional modification(s) of the receptor itself that
HEK 293 cells stably expressing either the FLAG-tagged m or chi-change the apparent functional receptor reserve inde-
meric receptor were grown in DMEM 1 10% fetal bovine serum topendent from changes in total receptor number.
80% confluency in 10 cm dishes and then starved for 1 hr in phos-
In conclusion, we have demonstrated that individual phate-free, serum-free media. Cells were metabolically labeled for
opiate drugs differ significantly in their effects on the 3 hr with 32P orthophosphate (Amersham Life Sciences, 0.25 mCi/
ml) and then incubated in the presence or absence of agonist forrapid regulation of opioid receptors, and that these dif-
30 min. Cells were washed two times with ice-cold PBS and lysedferences can be dissociated both pharmacologically
in 1 ml/dish extraction buffer (25 mM HEPES [pH 7.4], 50 mM NaCl,and mutationally from differences among individual ago-
0.1% Triton X-100, 1 mM CaCl2, 50 mM NaF, 80 mM b-glycerolnists in their ability to bind to and activate receptors.
phosphate, 0.1 mM sodium orthovanadate, 1 mg/ml leupeptin, 1 mg/
Moreover, mechanisms that underlie agonist-specific ml pepstatin A, 2 mg/ml aprotinin, and 2 mg/ml phenylmethylsulfonyl
differences in opioid receptor regulation by endocytosis fluoride), and receptors were immunoprecipitated from extracts us-
ing M1 anti-FLAG monoclonal antibody (Kodak Scientific Imagingoperate in native neurons. Thus, we have defined a func-
Systems) and protein A-Sepharose (Amersham Pharmacia Biotech)tional property of opiate ligands that may be of funda-
at 48C for 2 hr. Immunoprecipitates were washed extensively in lysismental importance to neural signal transduction and
buffer without phosphatase and protease inhibitors, treated withthat suggests a significant revision of our understanding
PNGase F (New England Biolabs) in 10 mM Tris (pH 7.4) for 2 hr at
of the biological mechanisms underlying drug tolerance 378C and were resolved by SDS±PAGE.
and addiction.
Arrestin Recruitment
HEK 293 cells stably expressing m or chimeric receptor were tran-Experimental Procedures
siently transfected with GFP±arrestin (Barak et al., 1997), and al-
lowed to recover for 24 hr. Cells were then plated to coverslips andCell Culture and Immunocytochemistry
allowed to grow for 24 hr. Cells were fed M1 anti-FLAG antibodiesHEK 293 cells (ATCC) were grown in DMEM supplemented with
(Kodak Scientific Imaging Systems) for 30 min (1:1000, 3 mg/ml) to10% fetal bovine serum (UCSF Cell Culture Facility). Cells were
label receptors in the plasma membrane and then treated with ago-stained for receptor as previously described (Whistler and von Zas-
nist for 10 min. Cells were fixed and permeabilized as previouslytrow, 1998). Hippocampal cultures were prepared and maintained
described (Whistler and von Zastrow, 1998) and then stained forin neurobasal media with 4% B27 as previously described (Lissin et
receptor with Texas red±conjugated donkey anti-mouse secondaryal., 1998). Three-week-old cultures were infected with a replication-
antibody (1:500, Jackson Immunoresearch). GFP-tagged arrestindefective adenovirus encoding the FLAG-tagged murine m or chi-
and antibody-labeled receptor were visualized by conventionalmeric opioid receptor (gift of Dr. Stephen Hardy) for 45 min, washed
epifluorescence microscopy using a Nikon inverted microscopethree times, and cultured for 48 hr prior to ligand application and
equipped with a 603 NA1.4 objective and standard filter setsimmunocytochemical staining.
(Omega Optical) allowing specific visualization of both fluorophores
without detectable bleedthrough.
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